MedTrace Logo

Broccoli Sprout Extract in Treating Patients With Breast Cancer

NCT01753908 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-10-31

No results posted yet for this study

Summary

This randomized pilot trial studies broccoli sprout extract in treating patients with breast cancer. Broccoli sprout extract contains ingredients that may prevent or slow the growth of certain cancers. Studying samples of tissue from patients receiving broccoli sprout extract may help determine if it can enter breast tumor cells and how it affects certain biomarkers.

Conditions

  • Ductal Breast Carcinoma
  • Ductal Breast Carcinoma In Situ
  • Estrogen Receptor Negative
  • Estrogen Receptor Positive
  • Invasive Breast Carcinoma
  • Lobular Breast Carcinoma
  • Postmenopausal
  • Stage IA Breast Cancer
  • Stage IB Breast Cancer
  • Stage IIA Breast Cancer
  • Stage IIB Breast Cancer

Interventions

DRUG

Broccoli Sprout Extract

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Urinary ITCs and metabolites measured

OTHER

Placebo

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Roswell Park Cancer Institute

    lead OTHER

Principal Investigators

  • Jessica Young · Roswell Park Cancer Institute

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-21
Primary Completion
2018-07-23
Completion
2018-08-23

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01753908 on ClinicalTrials.gov